Short Interest in Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Expands By 169.9%

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 27,721 shares, a growth of 169.9% from the June 30th total of 10,271 shares. Based on an average daily volume of 10 shares, the short-interest ratio is currently 2,772.1 days.

Laboratorios Farmaceuticos Rovi Price Performance

Shares of LABFF remained flat at C$64.77 on Tuesday. The stock has a 50-day simple moving average of C$65.67 and a two-hundred day simple moving average of C$65.79. Laboratorios Farmaceuticos Rovi has a one year low of C$65.86 and a one year high of C$65.86.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.